EUR 2.85
(-2.9%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 40.33 Million CAD | -6.57% |
2022 | 43.16 Million CAD | 0.03% |
2021 | 43.15 Million CAD | 52.03% |
2020 | 28.38 Million CAD | 43.82% |
2019 | 19.73 Million CAD | 113901.04% |
2018 | 17.31 Thousand CAD | -20.7% |
2017 | 21.83 Thousand CAD | -13.49% |
2016 | 25.23 Thousand CAD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 30.15 Million CAD | 368.83% |
2024 Q1 | 28.66 Million CAD | -99.38% |
2024 Q3 | 30.21 Million CAD | -84.76% |
2023 Q3 | 37.25 Million CAD | -5.99% |
2023 Q1 | 41.23 Million CAD | -4.48% |
2023 Q2 | 39.62 Million CAD | -3.9% |
2023 FY | 40.33 Million CAD | -6.57% |
2023 Q4 | 40.33 Million CAD | 8.27% |
2022 FY | 43.16 Million CAD | 0.03% |
2022 Q4 | 43.16 Million CAD | -3.11% |
2022 Q3 | 44.55 Million CAD | 0.88% |
2022 Q2 | 44.16 Million CAD | -1.1% |
2022 Q1 | 44.65 Million CAD | 3.48% |
2021 Q2 | 42.69 Million CAD | -28.63% |
2021 Q4 | 43.15 Million CAD | 2.42% |
2021 Q3 | 42.13 Million CAD | -1.31% |
2021 FY | 43.15 Million CAD | 52.03% |
2021 Q1 | 59.81 Million CAD | 110.73% |
2020 Q1 | 29.34 Million CAD | 48.7% |
2020 Q4 | 28.38 Million CAD | 4.73% |
2020 Q2 | 22.66 Million CAD | -22.78% |
2020 Q3 | 27.1 Million CAD | 19.6% |
2020 FY | 28.38 Million CAD | 43.82% |
2019 FY | 19.73 Million CAD | 113901.04% |
2019 Q4 | 19.73 Million CAD | -15.48% |
2019 Q1 | 10.17 Million CAD | 58697.97% |
2019 Q3 | 23.35 Million CAD | 29.28% |
2019 Q2 | 18.06 Million CAD | 77.44% |
2018 FY | 17.31 Thousand CAD | -20.7% |
2018 Q4 | 17.31 Thousand CAD | 0.0% |
2018 Q1 | - CAD | -100.0% |
2018 Q3 | - CAD | 0.0% |
2017 Q4 | 21.83 Thousand CAD | 0.0% |
2017 FY | 21.83 Thousand CAD | -13.49% |
2016 FY | 25.23 Thousand CAD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 25.76 Million EUR | -56.531% |
Redcare Pharmacy NV | 236.04 Million EUR | 82.914% |